Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Core Viewpoint - Curis, Inc. has successfully closed a private placement financing, raising gross proceeds of up to $80.8 million, which will support the development of its lead drug emavusertib [1][2]. Group 1: Financing Details - The private placement included initial gross proceeds of approximately $20.2 million before placement agent fees and offering expenses [1]. - The financing was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP, along with participation from other institutional investors and members of the management team and board of directors [2]. Group 2: Company Overview - Curis, Inc. is focused on developing emavusertib, an orally available small molecule IRAK4 and FLT3 inhibitor [3]. - Emavusertib is currently being evaluated in clinical studies for various types of lymphoma and leukemia, including a Phase 1/2 study in combination with ibrutinib for relapsed/refractory primary central nervous system lymphoma and a Phase 2 study in chronic lymphocytic leukemia [3]. - The drug has received Orphan Drug Designation from the U.S. FDA and the European Commission for the treatment of primary central nervous system lymphoma, acute myeloid leukemia, and myelodysplastic syndromes [3].